To Jump Start China, Think Commercial: Amgen Ties Knot With Beta Pharma For Vectibix
This article was originally published in PharmAsia News
Executive Summary
Since fixing its eyes on China, Amgen has been scouting the country for deals. Now the first result is in, a JV with local industry darling Beta Pharma to commercialize Vectibix in China.
You may also be interested in...
Insider Analysis From Easton Associates: Are Patient Assistance Programs The Silver Bullet To Meet Affordability Challenges In China?
By Celia Deng, Zhiyi Tong and Paul Zhang
Lilly Snatches ImClone Away From Bristol
Lilly’s $6.5 billion acquisition of ImClone will create an oncology “powerhouse” with 18 cancer drugs in clinical development.
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.